Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageVir Biotechnology, Inc. (including its subsidiaries, referred to as “Vir Bio,” “the Company,” “we,” “our” or “us”) is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. These diseases represent formidable challenges to human health. Under normal conditions, our immune system is naturally equipped to protect us by identifying and eradicating both cancer cells and viruses.
In the company’s own words · 10-K filed Feb 23, 2026 · SEC EDGAR
Business segments
Q2 2025 · $1.7MThe company’s own SEC segment disclosure.
- Contract$1.5M89%
- Grant$183.0K11%
For the full year FY2025, revenue was $69M (−7.6% year on year) and net income −$438M. Its largest product in 2025-Q2 was Contract at $1.5M, 89% of the disclosed total, just ahead of Grant at 11%.
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.